A B S T R A C T Previous studies from our laboratory indicated that both beta-adrenergic and cholinergic agents stimulate in vivo secretion by rat bronchiolar Clara cells. Those studies also provided support for an in-series beta-adrenergic-cholinergic stimulation of secretion. To further explore the regulation of secretion in Clara cells, and to do it in the absence of systemic influences, we have used the isolated ventilated perfused rat lung. We have again used morphometry and electron microscopy to assess secretion by measuring the volume density (fraction of cell volume) of the secretory granules of bronchiolar Clara cells. We found that in the isolated perfused lung, as in the intact animal, isoproterenol stimulated secretion in Clara cells and that this effect was blocked by the betaadrenergic antagonist propranolol. Pilocarpine, unlike its action in the intact animal, did not stimulate secretion in the isolated lung; rather it inhibited the secretory effect of isoproterenol. Increased tidal-volume ventilation stimulated secretion; propranolol did not block this effect. Analogs of cyclic (c)AMP and of cGMP also stimulated secretion by Clara cells. These findings indicate that there are at least two mechanisms by which Clara cells can be stimulated to secrete. One seems to be beta-adrenergic-cAMP mediated but the triggering event is unknown. The other is initiated by increased tidal volume and cGMP may be involved in the intracellular mediation ofthis stimulatory event. Finally, we found evidence of beta-adrenergic
INTRODUCTION
Clara cells are epithelial cells which have ultrastructural characteristics of cells with a major secretory function (1) (2) (3) (4) (5) . They are located mainly in small conducting airways (3) (4) , and are thought to secrete components of the extracellular lining of these airways (6) . The extracellular lining of this region may be of particular importance because noxious agents inhaled into the lung commonly affect these airways (7) , and because these airways are the site of obstruction early in the course of very common diseases such as chronic bronchitis and emphysema (8) . In an effort to improve our understanding of this region of the lung, we used ultrastructural morphometric methods to study the in vivo regulation of secretion in Clara cells of rats (9) . We found that both pilocarpine and isoproterenol stimulated secretion, as evidenced by a fall in the volume density (fraction ofcell volume) ofthe secretory granules in these cells; atropine and propranolol, respectively, blocked secretion stimulated by these agonists. We found unexpectedly that propranolol, a beta-adrenergic antagonist, was as effective as atropine in blocking the stimulation of secretion produced by pilocarpine. This suggested that an in-series cholinergic-adrenergic mechanism might be involved in the regulation of Clara cell secretion.
The in vivo nature of our previous studies limited further delineation of this potential regulatory mechanism; we could not, for example, control the potential systemic effects of the pharmacological agents on Clara cell secretion or determine if the secretagogues were acting in series within the lung or if one arm of the in-series stimulatory mechanism was extrapulmonary. We have therefore undertaken the present study using the isolated ventilated perfused lung (IVPL)1 as a system with which we might explore the regulation of Clara cell secretion in the absence of potential systemic influences on secretion.
METHODS
Animals. We used male Long-Evans-descent hooded rats weighing between 200-250 g (Charles River Breeding Laboratories, Inc., Wilmington, Mass.). They were maintained on a 12-h light-12-h dark cycle and were allowed food (Wayne Lab-Blox, Allied Mills, Inc., Chicago, Ill.) and water ad lib.
Isolated ventilated perfused lung system. The animals were anesthetized by giving pentobarbital sodium (30 mg/kg) intraperitoneally, and were killed by exsanguination while the lung was excised and placed in the perfusion chamber. The method ofperfusing and ventilating the isolated lung has been previously described in detail (10) . In essence, the excised lungs were kept at 37°C, and ventilated at 40 breaths/min with warm humidified gas (95% 02:5% C02) at a tidal volume based on the rat's body weight (11) . We used Krebs-Ringer bicarbonate medium (12) containing fatty-acidpoor 5% bovine serum albumin, as the perfusion medium. The perfusate (40 ml) also contained glucose (5 mM) and normal rat plasma levels of 20 amino acids (13) . The perfusate was delivered to the lung at a pressure of 20 cm of water and was recirculated.
Experimental procedures. The drugs were added to the perfusate to achieve the following concentrations: pilocarpine (0.5 mM), atropine (0.5 mM), DL-isoproterenol (0.5 mM or 5 ,uM), propranolol (0.5 mM), N f02-dibutyryl adenosine 3':5' cyclic monophosphoric acid (1.0 mM), N602-dibutyryl guanosine 3':5' cyclic monophosphoric acid (1.0 mM), 8-bromoadenosine 3':5' cyclic monophosphoric acid (1.0 mM), and 8-bromoguanosine 3':5' cyclic monophosphoric acid (1.0 mM). Control lungs were perfused with drug-free perfusate.
After 1 h, the perfusion was stopped and the lungs were removed from the chamber. We immediately infused 2.5% cold glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7 .4, into the trachea at a transpulmonary pressure of 20 cm H20. The trachea was then ligated and fixation was continued as previously described (9) .
Electron microscopic and morphometric procedures. The methods of preparing lung tissue for electron microscopic examination, the tissue sampling procedures and the criteria for identification of Clara cells were identical in the present study to those previously described in detail (9, 14, 15) . Morphometric analysis was performed using the methods of Weibel (16) . We used a double-lattice test system instead of the multipurpose test system used in our prior report (9) ; the morphometric procedures were otherwise the same as those used previously (9) . The volume density ofthe secretory granules relative to the cell was calculated by dividing the number of test-system points which fell over the secretory granules by the number of test points which fell over the entire cell (including the secretory granules) (16) , and multiplying this quotient by 100. It can be appreciated from this calculation that a change in the volume density could occur either because of an absolute change in the volume of secretory granules or from a change in cell volume without any change in the volume of secretory granules. To help exclude the second possibility, we have also ex- ' Abbreviation used in this paper: IVPL, isolated ventilated perfused lung. pressed the volume density as a function of the test points that fell on the secretory granules relative to the fixed number ofpoints on the test system. As before (9) the surface-to-volume ratio of the secretory granules was calculated by a standard method (16) .
Lung weight. In some experiments the weight of the lung was measured at the end of the perfusion, after conducting airways had been removed at the hilum. The lung's dry weight was then obtained by heating pieces of lung at 600C until two weights, 24 h apart, remained the same.
ATP measurements. At the end of the perfusion, the lungs were rapidly frozen by clamping them between blocks of aluminum cooled to the temperature of liquid nitrogen. Pieces of frozen lung (0.2-0.3 g) were quickly ground to a fine powder at the temperature of liquid N2 and then immediately homogenized in 0.4 M perchloric acid at 0-4°C. The homogenized samples were kept on ice for 15 min and then centrifuged at 0°C at 15,000g for 20 min. The acidsoluble supernatant material was collected and KOH added to it to bring its pH to between 5 and 7. These samples were kept on ice for 30 min to precipitate potassium chlorate. After another centrifugation at 0°C and 15,000 g for 20 min, the supernatant fluid was removed and immediately frozen for later determination of ATP using enzymatic methods: glucose-6-phosphate dehydrogenase and hexokinase (17) . To determine the recovery of ATP in the assay procedure, we added a known amount of ATP to another piece of lung and subjected it to the same procedures.
Statistical analysis. For each parameter measured or calculated from these measurements, the values for individual animals were averaged per experimental group and the standard error of the group mean calculated (18) . An analysis of variance was used for multiple group comparisons (19) and Duncan (21) were used to test for significant differences between groups. An unpaired t-test analysis was used to compare means of two groups.
RESULTS
Characteristics of the isolated ventilated perfused lung system. The lung dry weight, lung weight-tobody weight ratio and the ATP content of the lungs (Table I) were virtually the same as those reported by others using similar rat lung preparations (22) (23) (24) (25) (26) . The fall in the flow rate of the perfusate of control lungs during the experiment was the same or less than that reported by others (26) ; the fall in the flow rate in lungs perfused with isoproterenol plus propranolol was greater than the decrease that occurred in control lungs. There was a 13% decrease in the percent dry weight in the lungs perfused with isoproterenol plus propranolol and in the lungs perfused with pilocarpine (P < 0.05 compared to control lungs). The ATP content of the lungs was the same under the different conditions in which it was measured.
In an attempt to obtain a more direct comparison of the effect on the Clara cell of in vitro ventilation and perfusion, we compared the volume density of secretory granules and of mitochondria in Clara cells after 1 h of in vitro perfusion and ventilation to values we had previously developed for Clara cells in lungs fixed immediately after killing (9) . We found the following: for lungs fixed immediately after killing, the volume density for secretory granules and for mitochondria of Clara cells from control rats was 4.2+0.3% (n = 3) and 8.0+0.3% (n = 3), respectively; the values for the same organelles in Clara cells from control IVPL were 3.7±0.5% (n = 6) and 7.8±0.5% (n = 3), respectively.
The differences between the same organelles in these two groups were not statistically significant (P > 0.05). We wish to point out that the measurements in lungs fixed immediately after sacrifice were performed using a multipurpose test system (9) (9) . In contrast to those results, pilocarpine did not cause a fall in the volume density of the secretory granules when used in the IVPL (Fig. 1) . Although the differences were not significant, the slightly greater value for the volume density in the lungs exposed to pilocarpine and the virtually identical value of control compared to the lungs exposed to 5.0F pilocarpine and atropine suggested that pilocarpine might in fact be exerting an inhibitory effect on secretion (vide infra [n = 4]). ,-adrenergic effect and /3adrenergic-cholinergic interaction. Isoproterenol (0.5 mM) caused a marked fall in the volume density of the secretory granules and this fall was blocked by propranolol (Fig. 2) ; isoproterenol (5 ,uM) also caused a fall in the volume density to a value of 2.0 (not shown). Our results ( Fig. 1) suggested that in the IVPL pilocarpine exerted an inhibitory effect on secretion. When we found that isoproterenol did stimulate Clara cell secretion we thought we could test more rigorously if pilocarpine inhibited secretion by observing its influence on isoproterenol-stim'ulated secretion. We found that pilocarpine inhibited the fall in secretory granule volume density produced by isoproterenol (Fig. 2) Effect of ventilatory volume. A twofold increase in ventilatory volume produced a 50% fall in the volume density of secretory granules of the Clara cell; propranolol did not block the effect of ventilation (Fig. 4) . The effects of these manipulations were similar when the volume density was expressed relative to the test system: control ( 
DISCUSSION
The results ofprevious experiments on intact rats led us to suggest that secretion by Clara cells might be mediated by cholinergic and adrenergic effectors arranged in series (9) . The initial aim ofthe present study, to further explore this possibility, required that Clara cells be removed from systemic influences. The IVPL seemed to be an appropriate means to meet this requirement because: (a) using the IVPL avoids exposing cells to proteases, as would be required to isolate Clara cells; (b) in the IVPL Clara cells maintain nearly normal anatomical relations to other cellular as well as extracellular components of the lung; and (c) finally, Clara cells in the IVPL are studied under working conditions, i.e., while the lung is being ventilated.
The IVPL, however, has certain potential disadvantages, including the ease with which it develops edema (22) . We think that lungs in our control group did not have more than, at most, a minimal amount of edema. The reasons for this conclusion are (a) their percent dry weight was the same after 1 h of perfusion as we previously found at the onset of perfusion (10) , (b) the ratio of lung weight to body weight was the same after 1 h of perfusion as in freshly excised lungs (23) , and (c) the percent dry weight (18%) of control lungs was only slightly lower than predicted for bloodless lungs (24) .
By these criteria the lungs in our control group and the lungs perfused with isoproterenol would be considered virtually free of edema. Lungs perfused with isoproterenol plus propranolol or with pilocarpine alone, did have edema as evidenced by the percent dry weight and by the fall in flow rate. We do not think the development of edema with propranolol plus isoproterenol limits the interpretation of our results, because propranolol, in spite of the edema, still acted as a beta-adrenergic antagonist. We cannot exclude the possibility that edema interfered with the reaction of pilocarpine in those lungs perfused with this drug, but we think this rather unlikely because the degree of edema is relatively small and because there was no change in the rate of flow of the perfusate.
Our second concern was with the degree to which the lungs' energy metabolism may have become impaired during perfusion. The ATP content after 60 min of perfusion (Table I) (9) was mediated by an extrapulmonary mechanism. An alternative explanation for the in vivo effect of pilocarpine is that it altered ventilation or pulmonary blood flow and that these changes in some way stimulated Clara cell secretion.
We have so far found that three pharmacological agents (isoproterenol, cAMP, and cGMP) and one mechanical event (increased ventilatory volume) stimulate Clara cell secretion. The effect of isoproterenol and of cAMP are consistent with the findings in other tissues (25) , in alveolar type 2 cells (26) , and with the notion that cAMP is the intracellular mediator of the stimulatory effect on secretion of beta-adrenergic agonists; these results are also in accord with the observations that beta-adrenergic agonists increase the cAMP content of the lung (27, 28) .
The mechanism by which pilocarpine inhibits the secretory effect of isoproterenol in the IVPL is unclear. Precedent for such an inhibition exists in the inhibition by muscarinic agonists of isoproterenol-stimulated cAMP accumulation in heart (29) . However, to invoke this mechanism in the lung we must reconcile the cholinergic increase of the cGMP content of the lung (27) and our finding that analogs of cGMP stimulate Clara cell secretion. This apparent paradox could be explained by cellular or intracellular compartmentalization of the response of the cyclic nucleotides to adrenergic or cholinergic stimuli. Thus, although cholinergic agonists increase the cGMP content of the lung as a whole, they might not effect Clara cells the same way. Alternatively, pilocarpine might increase the cGMP content of Clara cells, but the eGMP produced could occupy receptor sites not related to Clara cell secretion; evidence for such a functional coinpartmentalization has been obtained from studies on isolated Leydig cells (30) .
The stimulation of Clara cell secretion by increased ventilatory volume is interesting because increased tidal volume ventilation accelerates the rate of upward movement of the extracellular material lining pulmonary airspaces (31, 32) . Greater rates of secretion during periods of increased tidal volume ventilation might be needed to meet the larger replacement requirement engendered by more rapid loss. The failure of propranolol to block the secretory effect of increased tidal volume breathing indicates this ventilatory event is not mediated by a beta-adrenergic mechanism.
The secretory effect of increased tidal volume and of cGMP are of particular interest when considered together and viewed in light of the report that large volume ventilation markedly increases the cGMP content of the lung (33) . These observations suggest that cGMP may be involved in the intracellular mediation of the mechanico-secretion coupling. The triggering mechanism responsible for stimulating the increase in cGMP is unknown; possible initiating factors iniclude mechanical deformation of the plasma membrane of the Clara cells, and the effect on1 Clara cells of bioactive materials released by mechanical deformation of the lung (34, 35) .
In summary, our work suggests that there are at least two mechanisms by which Clara cells can be stimulated to secrete. One seems to be beta-adrenergic-cAMP mediated by the triggering event in unknown. The other is initiated by an increase in tidal volume; cGMP may participate in the intracellular mediation of this stimulus. Finally, we have found evidence for betaadrenergic (stimulatory) -cholinergic (inhibitory) antagonism in the regulation of Clara cell secretion.
